TBC1D3F Activators

Forskolin, by elevating intracellular cAMP, activates protein kinase A (PKA), which then phosphorylates target proteins that could intersect with the signaling cascades involving TBC1D3F. PMA directly stimulates protein kinase C (PKC), a pivotal enzyme in the regulation of proteins that may be part of the TBC1D3F-related signaling network. Ionomycin, a calcium ionophore, raises the levels of intracellular calcium, a secondary messenger that activates calcium-dependent kinases, potentially influencing the TBC1D3F protein by modulating the calcium signaling pathways. Meanwhile, the inhibitor LY294002 targets phosphatidylinositol 3-kinase (PI3K), affecting the AKT signaling pathway and indirectly impacting the cellular pathways associated with TBC1D3F. Rapamycin, by inhibiting mammalian target of rapamycin (mTOR), can alter downstream signaling pathways that influence TBC1D3F.

The introduction of A23187 disrupts intracellular calcium balance and could affect TBC1D3F through calcium-sensitive signaling cascades. U73122, which inhibits phospholipase C, and Okadaic Acid, which inhibits protein phosphatases PP1 and PP2A, result in altered phosphorylation states within the cell, potentially affecting the pathways TBC1D3F is part of. Compounds like Go 6983, which modulates PKC activity, SB 203580, an inhibitor of p38 MAP kinase, KN-93, a calmodulin-dependent kinase II (CaMKII) inhibitor, and PD98059, a MEK inhibitor, all serve to influence the cellular signaling landscape.